The patient experienced a complete clinical response (CR); however, the MRD was persistent and did not clear after 4 months of azacitidine; MRD was confirmed on a marrow biopsy. The patient then entered on the phase 1 trial and received lymphodepletion before receiving 1.8 billion CYNK-00...
CYNK-001 administered via the intracranial (IC) route exhibitedinvivoantitumor activity in a U-87MG orthotopic mouse model.Methods:A Phase I/IIa clinical trial is enrolling IDH1 wild-type GBM patients at first or second recurrence with contrast-enhancing measurable disease (per RANO criteria) who...
Celularity, a clinical-stage biotechnology company, announced that the company has received Fast Track Designation from the US Food and Drug Administration (FDA) for its non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer (NK) cell therapy, CYNK-001, fo...